default author photo

Aleix Prat

Hospital Clinic of Barcelona - Department of Medical Oncology

The August Pi i Sunyer Biomedical Research Institute (IDIBAPS) - Translational Genomics and Targeted Therapeutics in Solid Tumors

Barcelona

Spain

Hospital Clinic of Barcelona - Department of Medical Oncology

Barcelona

Spain

Department of Medicine - University of Barcelona

Spain

  • The August Pi i Sunyer Biomedical Research Institute (IDIBAPS) - Translational Genomics and Targeted Therapeutics in Solid Tumors

  • Hospital Clinic of Barcelona - Department of Medical Oncology

  • Department of Medicine - University of Barcelona

SCHOLARLY PAPERS

5

DOWNLOADS

228

TOTAL CITATIONS

0

Scholarly Papers (5)

Actions:
Email selected abstracts
1.

Chemotherapy De-Escalation Using an 18F-FDG PET/CT–Based, Pathologic Response–Adapted Strategy in HER2-Positive Early Breast Cancer: The PHERGain Trial

Number of pages: 38 Posted: 02 Dec 2020
José Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, Agostina Stradella, Begoña Bermejo, Peter Schmid, Frederik Marmé, Santiago Escrivá de-Romani, Lourdes Calvo, Nuria Ribelles, Noelia Martinez, Cinta Albacar, Aleix Prat, Florence Dalenc, Kerrou Khaldoun, Marco Colleoni, Noemi Afonso, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Cortés, Antonio Llombart-Cussac and PHERGain Steering Committee and Trial Investigators
Quiron Group - International Breast Cancer Center (IBCC), Université Libre de Bruxelles (ULB) - Institute Jules Bordet, Hospital Universitario Virgen del Rocío - Medical Oncology Department, Institut Català d'Oncologia, Hospital Clínico Universitario de Valencia, Queen Mary University of London - Barts ECMC, Leitung Sektion Translationale Gynäkologische Onkologie Nationales Centrum für 27 Tumorerkrankungen und Universitätsfrauenklinik Heidelberg, Vall d'Hebron University Hospital - Breast Cancer Group, Hospital Universitario A Coruña - UGC Oncología Intercentros, Hospital Universitario Virgen de la Victoria, Universidad de Alcalá, IRYCIS, Hospital Universitari Sant Joan de Reus - Department of Medical Oncology, Hospital Clinic of Barcelona - Department of Medical Oncology, Institut Claudius Regaud - IUCT-Oncopole, CRCT, Inserm, Sorbonne University - Tenon Hospital, Nuclear Medicine and PET Center Department, European Institute of Oncology (IEO) - Division of Medical Senology, Universidade do Porto - Centro Hospitalar, Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Vall d'Hebron Institute of Oncology, Universidad Catolica - Hospital Arnau de Vilanova and Independent
Downloads 77 (830,555)

Abstract:

Loading...

Trastuzumab; Pertuzumab; De-escalation; Pathologic complete response; FDG-PET/CT; HER2-positive; Early breast cancer

2.

Molecular Characterisation of the Residual Disease after Neoadjuvant Endocrine Therapy in Er+/Her2- Breast Cancer Uncovers Biomarkers of Tumour Response

Downloads 61 (1,000,027)

Molecular Characterisation of the Residual Disease after Neoadjuvant Endocrine Therapy in Er+/Her2- Breast Cancer Uncovers Biomarkers of Tumour Response

Number of pages: 32 Posted: 03 Dec 2024
Joanna I. López-Velazco, Sara Manzano, Kepa Elorriaga, Maria Otaño, Ainhara Lahuerta, Luis Álvarez, Inge Etxabe, Miren Huarte, Elvira Buch, Julia Gimenez, Vanesa Quiroga, Marta Fernandez, Sofía Aragón, Laia Paré, Aleix Prat, Isabel Álvarez-López, MARIA CAFFAREL and Ander Urruticoechea
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital Duran i Reynals (ICO) - Catalan Institute of Oncology, affiliation not provided to SSRN, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Universidad de Barcelona - Hospital Clínic Barcelona, Hospital Clinic of Barcelona - Department of Medical Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 36 (1,296,409)

Abstract:

Loading...

Neoadjuvant endocrine therapy, aromatase inhibitors, ER+/HER2- breast cancer, PAM50, normal-like subtype, ROR, p53

Molecular Characterisation of the Residual Disease after Neoadjuvant Endocrine Therapy in Er+/Her2- Breast Cancer Uncovers Biomarkers of Tumour Response

Number of pages: 32 Posted: 16 Apr 2025
Joanna I. López-Velazco, Sara Manzano, Kepa Elorriaga, Maria Otaño, Ainhara Lahuerta, Luis Álvarez, Inge Etxabe, Miren Huarte, Elvira Buch, Julia Gimenez, Vanesa Quiroga, Marta Fernandez, Sofía Aragón, Laia Paré, Aleix Prat, Isabel Álvarez-López, MARIA CAFFAREL and Ander Urruticoechea
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital Duran i Reynals (ICO) - Catalan Institute of Oncology, affiliation not provided to SSRN, Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, Universidad de Barcelona - Hospital Clínic Barcelona, Hospital Clinic of Barcelona - Department of Medical Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 25 (1,473,203)

Abstract:

Loading...

Neoadjuvant endocrine therapy, Aromatase inhibitors, ER+/HER2- breast cancer, PAM50

3.

Pre-Operative Ribociclib Plus Letrozole Versus Chemotherapy: Health-Related Quality of Life Outcomes from the SOLTI CORALLEEN Trial

Number of pages: 15 Posted: 30 Jun 2022
Guillermo Villacampa Javierre, Claudette Falato, Laia Paré, Cristina Hernando, Miriam Arumí, Cristina Saura, Guadalupe Gómez Melis, Montserrat Muñoz, Miguel Gil-Gil, Yann Izarzugaza, Neus Ferrer, Josu Najera-Zuloaga, Alvaro Montaño, Eva Ciruelos, Santiago González-Santiago, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat and Tomas Pascual
SOLTI Breast Cancer Research Group, SOLTI Breast Cancer Research Group, SOLTI Breast Cancer Research Group, Hospital Clínico de Valencia, Vall d'Hebron Institute of Oncology, Vall d’Hebron Institute of Oncology (VHIO), Universitat Politécnica de Catalunya, Hospital Clinic of Barcelona - Department of Medical Oncology, Hospitalet de Llobregat - Department of Medical Oncology, Hospital Universitario IIS-Fundación Jiménez Díaz (IIS-FJD, UAM)/CIBERER, Hospital Universitari Son Espases, University of Deusto, University of Seville - Hospital Universitario Virgen del Rocío, SOLTI Breast Cancer Research Group, Hospital San Pedro de Alcántara, SOLTI Breast Cancer Research Group, SOLTI Breast Cancer Research Group, Hospital Clinic of Barcelona - Department of Medical Oncology and SOLTI Breast Cancer Research Group
Downloads 41 (1,196,171)

Abstract:

Loading...

Ribociclib, CDK 4/6 inhibitors, Quality of Life, patients-reported outcomes, Luminal B breast cancer

4.

Positioning of Tucatinib in the New Clinical Scenario of HER2-Positive Metastatic Breast Cancer: An Italian and Spanish Consensus Paper

Number of pages: 18 Posted: 19 Mar 2024
Pierfranco Conte, Eva Ciruelos, Giuseppe Curigliano, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Gennari, Antonio Llombart, Miguel Martin, Francesca Poggio, Aleix Prat, Fabio Puglisi and Cristina Saura
Istituto Oncologico Veneto – IRCCS, SOLTI Breast Cancer Research Group, European Institute of Oncology (IEO) IRCCS - Division of New Drugs and Early Drug Development for Innovative Therapies, IRCCS-Fondazione Bietti, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), University of Piemonte Orientale, Universidad Católica de Salta, - Hospital General Universitario Gregorio Marañón, IRCCS Ospedale Policlinico San Martino, Hospital Clinic of Barcelona - Department of Medical Oncology, Università degli Studi di Udine and Vall d’Hebron Institute of Oncology (VHIO)
Downloads 27 (1,372,601)

Abstract:

Loading...

breast cancer, HER2, tucatinib, TKI, brain metastases

5.

HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from a Real-World Cohort

Number of pages: 35 Posted: 11 Feb 2026
beatriz Alonso de castro, Sandra Cobo, María Alonso Pena, Julia Pérez Malillos, Cristina Reboredo Rendo, Eva Pérez López, Oleguer Castillo, Valeria Sirenko, Angela Aguirre, Paula Blasco, Lourdes Calvo Martínez, Patricia Galván, Esther Sanfeliu, Paula Saavedra Nieves, Ángel Concha López, Aleix Prat, Fara Brasó-Maristany and Silvia Antolín Novoa
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Instituto de Investigación Biomédica de A Coruña - Complexo Hospitalario Universitario A Coruña, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital Clinic of Barcelona - Department of Medical Oncology, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 22 (1,481,165)

Abstract:

Loading...

HER2, Breast Cancer, HER2DX, trastuzumab, pertuzumab, Pathological complete response, neoadjuvant